High dose brachytherapy with non sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single center preliminary results.
Paolo CastellucciF SavoiaA FarinaG M LimaA PatriziC BaraldiF ZagniS VichiC PettinatoA G MorgantiL StrigariS FantiPublished in: European journal of nuclear medicine and molecular imaging (2020)
High dose brachytherapy with Rhenium-SCT® is a noninvasive, reasonably safe, easy to perform, effective and well-tolerated approach to treat NMSCs, and it seems to be a useful alternative option when surgery or radiation therapy are difficult to perform or not recommended. In our population 98% of the treated lesions resolved completely after a single application and only one relapsed after 2 years. Larger patients' population and longer follow-up are needed to confirm these preliminary data and to find the optimal dose to administer in order to achieve complete response without significant side effects.
Keyphrases
- high dose
- radiation therapy
- low dose
- stem cell transplantation
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- minimally invasive
- acute lymphoblastic leukemia
- peritoneal dialysis
- acute myeloid leukemia
- multiple myeloma
- squamous cell carcinoma
- prognostic factors
- hodgkin lymphoma
- wound healing
- soft tissue
- patient reported outcomes
- coronary artery disease
- patient reported
- childhood cancer